Diverticulitis Disease Global Market Report 2024: Key Players, Demand Patterns And Forecasts 2033 | Pfizer Inc., Johnson and Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc

The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2033

The Business Research Company offers in-depth market insights through Diverticulitis Disease Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.

Market Size And Growth Forecast:
The diverticulitis disease market size has grown rapidly in recent years. It will grow from $1.68 billion in 2023 to $1.85 billion in 2024 at a compound annual growth rate (CAGR) of 10.4%. The growth in the historic period can be attributed to aging population, dietary habits, obesity, advancements in medical imaging.

The diverticulitis disease market size is expected to see strong growth in the next few years. It will grow to $2.65 billion in 2028 at a compound annual growth rate (CAGR) of 9.4%. The growth in the forecast period can be attributed to colonoscopy and endoscopy, increased awareness, minimally invasive procedures, personalized medicine. Major trends in the forecast period include preventive measures, enhanced diagnostic tools, collaborative care models, healthcare policy changes.

Get Free Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=12990&type=smp

Market Segmentation:
The main types of diverticulitis disease are uncomplicated and complicated. Uncomplicated diverticulitis refers to a medical condition characterized by inflammation or infection of small pouches (diverticula) that can form in the walls of the colon. The types of diagnosis are included, such as computed tomography (CT) scans, ultrasounds, urine tests and blood tests, that includes treatments types such as medications, surgery, supportive care, penicillin antibiotic, antibiotics, dietary supplements and intravenous (IV) fluids. It is used by several end-users, such as specialty centers, hospitals and research centers.

Major Driver - Increasing Demand For Diverticulitis Treatments Driven By Rising Digestive Disorders
Rising demand for drugs and treatments for digestive disorders is expected to propel the growth of the diverticulitis disease market going forward. Digestive disorders refer to a wide range of conditions that affect the digestive system, which is responsible for breaking down and absorbing nutrients from food. Digestive disorders, such as colorectal cancer, can increase the risk of diverticulitis by contributing to the formation of diverticula and promoting bacterial stagnation in the colon's pouches. For instance, in September 2022, according to the International Agency for Research on Cancer, a France-based government agency, it was estimated that by 2040, there would be 3.2 million new cases and 1.6 million deaths attributed to colorectal cancer each year, representing a significant increase from 1.9 million newly diagnosed patients and 930,000 deaths in 2020. Therefore, the rising demand for drugs and treatments for digestive disorders is driving the growth of the diverticulitis disease market.

Competitive Landscape:
Major players in the diverticulitis disease market are Pfizer Inc., Johnson and Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma, Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Company, Cipla Limited, Hikma Pharmaceuticals PLC, Endo Pharmaceuticals, Aspen Pharmacare, Zydus Lifesciences, Lupin Limited, Glenmark Pharmaceuticals, Alkem Laboratories, Torrent Pharmaceuticals Ltd.

Get Access To The Full Market Report -
https://www.thebusinessresearchcompany.com/report/diverticulitis-disease-global-market-report

Top Trend - Innovative Drug Development Spurs Advances In Diverticulitis Treatments
Major companies operating in the diverticulitis disease market are developing innovative drugs and getting them approved to sustain their position in the market. Drug development can lead to the development of more effective treatments for diverticulitis, reducing the risk of complications and improving patient outcomes. For instance, in April 2023, the United States Food and Drug Administration, a US-based federal organization, approved Seres' microbiota drug for recurrent gut infections. This drug is designed to treat recurring gut infections and prevent the recurrence of Clostridioides difficile (C. diff.) infections in adults aged 18 and over. The approval of Vowst was based on a clinical trial that enrolled 346 patients with recurrent CDI. The trial found that patients who received Vowst were significantly less likely to experience a recurrence of the infection than those who received a placebo. The drug is taken orally and is based on microbiota containing Firmicutes spores, which are known to contribute to a healthy microbiome that can resist C. diff. colonization.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Diverticulitis Disease Market Characteristics
3. Diverticulitis Disease Market Trends And Strategies
4. Diverticulitis Disease Market - Macro Economic Scenario
5. Diverticulitis Disease Market Size And Growth
…..
27. Diverticulitis Disease Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialize in various industries including manufacturing, healthcare, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.

This release was published on openPR.